N-Acetyl Cysteine in Trichotillomania

Brief Title

N-Acetyl Cysteine in Trichotillomania

Official Title

A Double-Blind, Placebo-Controlled Study of N-Acetyl Cysteine in Trichotillomania

Brief Summary

      This is a 12-week, double-blind study of N-Acetyl Cysteine in the treatment of
      trichotillomania
    

Detailed Description

      The goal of the proposed study is to evaluate the efficacy and safety of N-Acetyl Cysteine
      (NAC) in trichotillomania. Forty subjects with DSM-IV trichotillomania will receive 12 weeks
      of double-blind NAC or placebo. The hypothesis to be tested is that NAC will be effective and
      well tolerated in patients with trichotillomania compared to placebo. The proposed study will
      provide needed data on the treatment of a disabling disorder that currently lacks a clearly
      effective treatment.
    

Study Phase

Phase 2

Study Type

Interventional

Primary Outcome

Massachusetts General Hospital Hairpulling Scale

Condition

Trichotillomania

Intervention

Placebo

Study Arms / Comparison Groups

 N-Acetyl Cysteine

Description:  N-Acetyl Cysteine

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Status

Drug

Estimated Enrollment

50

Start Date

July 2006

Completion Date

September 2008

Primary Completion Date

September 2008

Eligibility Criteria

        Inclusion Criteria:

          -  men and women age 18-65;

          -  current DSM-IV trichotillomania

        Exclusion Criteria:

          -  unstable medical illness;

          -  history of seizures;

          -  myocardial infarction within 6 months;

          -  current pregnancy or lactation, or inadequate contraception in women of childbearing
             potential;

          -  any thoughts of suicide;

          -  lifetime history of DSM-IV bipolar disorder type I, dementia, or schizophrenia or any
             other DSM-IV psychotic disorder;

          -  previous treatment with N-Acetyl Cysteine;

          -  treatment with investigational medication or depot neuroleptics within 3 months, with
             fluoxetine within 6 weeks, or with other psychotropics within 2 weeks prior to study
             baseline;

          -  9) diagnosis of asthma
      

Gender

All

Ages

18 Years - 65 Years

Accepts Healthy Volunteers

No

Contacts

Jon E Grant, MD, JD, , 

Location Countries

United States

Location Countries

United States

NCT ID

NCT00354770

Organization ID

0604M85110

Responsible Party

Principal Investigator

Study Sponsor

University of Chicago

Study Sponsor

Jon E Grant, MD, JD, Principal Investigator, University of Minnesota

Verification Date

October 2016